pityriasis%20(tinea)%20versicolor
PITYRIASIS (TINEA) VERSICOLOR
Pityriasis (Tinea) versicolor is a fungal infection caused by Malassezia furfur. It is benign, superficial, and localized to the stratum corneum.
It may present as chronic or recurrent infection and may occur in healthy individuals.
It is more common in summer than winter months.
It presents with multiple well-demarcated macules or patches and finely scaled plaques with hypopigmentation or hyperpigmentation, hence the term "versicolor".
Lesions are usually found on the upper trunk, chest, back and shoulders, and may extend toward the neck, face and arms.
Drug Information

Indication: Tinea corporis, cruris & pedis. Pityriasis, versicolor. Cutaneous candidiasis. Seborrheic dermatitis.

Indication: Cryptococcal meningitis & infections at other sites (eg, pulmonary, cutaneous). Maintenance therapy to pre...

Elan-Forte
chlorhexidine hydrochloride + tolnaftate

Indication: Tinea pedis, tinea corporis, tinea cruris, tinea capitis, tinea versicolor.

Indication: Cyptococcosis including cryptococcal meningitis & infections of other site (eg, pulmonary, cutaneous infec...

Indication: Cryptococcal meningitis & infections at other sites (eg, pulmonary, cutaneous). Maintenance therapy in pre...

Indication: Treatment & prevention of cryptococcal meningitis & other cryptococcal infections; treatment of vag, o...

Indication: Topical treatment of dermatophyte skin infections. Topical treatment & prophylaxis of scalp infections.

Indication: Fungal skin infections caused by dermatophytes; yeast skin infections, especially caused by genus Candida; pit...

Indication: Vulvovag candidosis, pityriasis versicolor, dermatomycosis, oral candidosis, onychomycosis caused by dermatoph...

Indication: Topical treatment of superficial mycoses eg, dermatophytoses, tinea pedis, tinea cruris, tinea corporis, tinea...

3  /  9
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
5 days ago
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.